By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN2d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monogram Orthopaedics Inc (MGRM – Research ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback